• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Experience with providing ECMO support may influence COVID-19 related mortality

byJessie WillisandTeddy Guo
October 12, 2021
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Mortality rate increased from 36.9% to 51.9% from early 2020 (before May 1) to late 2020 (after May 2) for COVID-19 patients treated with ECMO.

2. Experienced centers in delivering ECMO had an almost 50% reduced mortality rate compared to inexperienced centers.

Evidence Rating Level: 2 (Good)

Study Rundown: ECMO (Extracorporeal membrane oxygenation) is a complex procedure in which a patient is connected to a machine that functions as the patient’s external heart and lungs. ECMO is a form of life support that allows time for the body to heal during acute respiratory distress, such as with COVID-19. ECMO was originally not recommended for the management of COVID-19, but subsequent studies supported its usage later in 2020. In this international study, the mortality of patients with COVID-19 placed on ECMO was collected from the ELSO registry and analyzed. Eligible patients were divided in three groups based on the center and time in which they received ECMO: before May 1st, 2020, from “early-adopting” centers (A1), after May 2nd, 2020 at the same “early-adopting” centers (A2), and after May 2nd at “late-adopting” centers which had not used ECMO previously for COVID-19 (B). Results showed that in-hospital mortality was significantly increased for COVID-19 patients receiving ECMO in the latter half of 2020 compared to the former. A limitation of this study is the lack of results related to disease severity of these patients. One theory for the increase in mortality would be that the patients put on ECMO did not respond to treatments that were more established later in the pandemic, indicating a more treatment-resistant lung disease. Additionally, the increased mortality between cohorts A2 and B (early vs. late-adopting) potentially indicate the experience needed for ECMO, with a reduction in mortality of almost 50% in experienced versus non-experienced centers.  These results help guide the future usage of ECMO in COVID-19.

Click to read the study in the Lancet

Click to read an accompanying editorial in the Lancet

Relevant Reading: Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports

RELATED REPORTS

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

BNT162b2 safe and efficacious in children 5 to 11 years of age

In-Depth [retrospective cohort]: This study used patient data from over 349 centers across 41 countries. There were 4812 patients which were included based on a criterion of ≥16 years of age and placed on ECMO in 2020 with a confirmed diagnosis COVID-19. 1182 patients received ECMO before May 1st, 2020 (A1) at “early-adopting” centers. 2824 patients received ECMO at the early-adopting centers after May 2nd, 2020 – Dec 31st, 2020 (A2). 806 patients received ECMO after May 2nd at late-adopting centers that had not previously used COVID prior to May 1st (B).  Parameters were based on the previous ELSO study from before May 1st which found little evidence for the effectiveness of ECMO in COVID-19. Patients in all groups were roughly 50 years old and 74% male. The risk factors between all groups were comparable and data was adjusted accordingly. Later in 2020, patients were more likely to receive non-invasive ventilation before initiating ECMO. The primary outcome was in-hospital mortality 90 days after initiating ECMO, which was noted to be: A1) 36.9% (95% CI 34.1-39.7), A2) 51.9% (50.0-53.8), B) 58.9% (55.4-62.3). The length of time ECMO was placed was also longer in A2 compared to A1 (30.7 days vs. 27.1 days, respectively). Furthermore, Experienced ECMO centers had a relative risk of mortality of 0.56 compared to that of inexperienced centers.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: covidCOVID-19 complicationsextracorporeal membrane oxygenationextracorporeal membrane oxygenation (ECMO)SARS-CoV-2
Previous Post

Increasing the number of SARS-CoV-2 immune family members associated with decreasing risk of infection in nonimmune individuals

Next Post

Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis

RelatedReports

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

May 13, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

May 13, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

BNT162b2 safe and efficacious in children 5 to 11 years of age

May 13, 2022
Masks for personal protection for SARS-CoV-2 infection
Chronic Disease

Adding mask recommendation did not significantly reduce the SARS-CoV-2 infection rate

May 13, 2022
Next Post
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities

Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis

Coffee Industry Must Find New Ways to Stay Afloat

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Efficacy and safety of therapeutic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.